^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    pING-hHER3FL

    i
    Other names: pING-hHER3FL
    Associations

    News

    Trials
    Company:
    Duke University
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    3ms
    Assessing the Immunogenicity of PING-hHER3FL (clinicaltrials.gov)
    P1, N=24, Recruiting, Herbert Lyerly | Trial completion date: Sep 2025 --> Jan 2026 | Trial primary completion date: Sep 2024 --> Jan 2025
    Trial completion date • Trial primary completion date
    |
    ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    ERBB3 expression
    |
    pING-hHER3FL
    9ms
    Assessing the Immunogenicity of pING-hHER3FL (clinicaltrials.gov)
    P1, N=24, Recruiting, Herbert Lyerly | Trial completion date: Mar 2025 --> Sep 2025 | Trial primary completion date: Mar 2024 --> Sep 2024
    Trial completion date • Trial primary completion date
    |
    ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    ERBB3 expression
    |
    pING-hHER3FL
    1year
    Assessing the Immunogenicity of pING-hHER3FL (clinicaltrials.gov)
    P1, N=24, Recruiting, Herbert Lyerly | Trial completion date: Dec 2024 --> Mar 2025 | Trial primary completion date: Dec 2023 --> Mar 2024
    Trial completion date • Trial primary completion date
    |
    ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    ERBB3 expression
    |
    pING-hHER3FL